智通财经APP获悉，泰格医药(03347)涨超7%，截至发稿，涨7.7%，报46.44港元，成交额2136.07万港 元。 消息面上，泰格医药发布2025年第三季度报告，该集团前三季度取得营业收入50.26亿元，同比减少 0.82%；归母净利润10.2亿元，同比增加25.45%。单看第三季度，该公司第三季度实现营业收入17.75亿 元，同比增加3.86%；归母净利润6.37亿元，同比增加98.73%。 ...

证券之星消息，10月29日，生物经济（970038）指数报收于2298.38点，涨0.92%，成交241.09亿元，换 手率1.39%。当日该指数成份股中，上涨的有27家，泰格医药以11.09%的涨幅领涨，下跌的有22家，开 立医疗以11.39%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 生物经济指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.81% | 222.83 | -1.00% | 2701.68 | 医药生物 | | sz000661 | 长春高新 | 5.41% | 117.55 | 0.90% | 479.53 | 医药生物 | | sz300759 | 康龙化成 | 4.66% | 34.05 | 6.51% | 605.48 | 医药生物 | | sz002252 | 十代史上 | 4.52% | 6.70 | 0.30% | S 444.75 | ...

证券之星消息，10月29日，中证医疗（399989）指数报收于7501.54点，涨1.01%，成交250.53亿元，换 手率1.55%。当日该指数成份股中，上涨的有27家，泰格医药以11.09%的涨幅领涨，下跌的有23家，开 立医疗以11.39%的跌幅领跌。 中证医疗（399989）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，中证医疗（399989）指数成份股当日主力资金净流入合计3.23亿元，游资资金净流出合 计2.27亿元，散户资金净流出合计9538.28万元。成份股资金流向详情见下表： | 中证医疗指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 14.78% | 106.04 | 2.00% | | 3163.98 | 医药生物 | | sz300760 ...

Core Viewpoint - The medical innovation sector is experiencing a structural recovery, with significant inflows into the Medical Innovation ETF and positive performance from key companies in the sector [1][2]. Group 1: Market Performance - On October 29, the Medical Innovation ETF (516820.SH) fell by 1.28%, with component stocks showing mixed results; Chuaning Biological (301301) led gains at 5.12%, while Ailis (688578) saw the largest decline at 5.13% [1]. - The Medical Innovation ETF has seen continuous net inflows over the past five days, with a peak single-day net inflow of 38.68 million yuan, totaling 66.42 million yuan and an average daily net inflow of 13.28 million yuan [1]. Group 2: Industry Trends - The pharmaceutical sector has undergone a prolonged valuation adjustment, but a significant structural recovery trend has emerged recently, supported by policies promoting commercial insurance development [1]. - The investment and financing landscape in the pharmaceutical sector is expected to recover, driven by a rebound in the secondary market, with continued positive sentiment in the CXO and upstream segments [1]. - Recent quarterly reports from several CXO companies, including WuXi AppTec, Tigermed, and others, indicate a positive outlook for the industry [1]. Group 3: Future Outlook - The CXO sector continues to show strong performance, with companies like WuXi AppTec and Boteng surpassing expectations in their quarterly results [2]. - The innovative drug sector is on a long-term upward trend, with opportunities arising from both domestic revenue growth and international expansion [2]. - The expectation of interest rate cuts in the U.S. is likely to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2].

Summary of Tigermed (3347.HK) Earnings Review and Industry Insights Company Overview - **Company**: Tigermed (3347.HK) - **Market Cap**: HK$37.3 billion / $4.8 billion - **Industry**: Clinical Research Organization (CRO) in China - **12-Month Price Target**: HK$62.10 for H-shares, Rmb77.10 for A-shares - **Current Price**: HK$43.12 for H-shares, Rmb53.54 for A-shares - **Upside Potential**: 44.0% for both share classes [1][1] Financial Performance - **3Q25 Revenue**: Rmb1.78 billion, up 3.9% year-over-year (y/y) and 5.3% quarter-over-quarter (q/q), exceeding Goldman Sachs' estimate of Rmb1.71 billion [1][1] - **Recurring Earnings**: Rmb115 million, slightly below the estimate of Rmb138 million, with an operating margin of 9.6% compared to the expected 10.9% [1][1] - **Net Profit**: Rmb637 million, a significant increase of 98.7% y/y, driven by investment income of Rmb207 million and fair value gains of Rmb413 million [1][1] - **Cash from Operations**: Rmb330 million in 3Q25, up from Rmb198 million in 1Q25 and Rmb210 million in 2Q25 [2][2] Industry Insights - **Growth Opportunities**: Management emphasized the structural growth potential in China's clinical CRO sector, aligning with global R&D standards. Increased business development (BD) activity and financing are expected to drive domestic clinical demand [2][2] - **New Orders**: As of September, net new orders grew at a mid-teens rate, totaling Rmb7 billion, with a notable increase in contributions from multinational corporations (MNCs) and domestic pharmaceutical clients [3][3] - **Clinical Trial Solutions (CTS)**: Revenue declined by 3% in 3Q, but gross margin remained soft at 23%. The decline was attributed to limited backlogs in domestic innovative drug projects and low new contract pricing [19][19] - **Clinical-Related Consulting Services (CRLS)**: Revenue rose 10% in 3Q, with gross margin at 31%. Strong order momentum from MNCs supported growth, although margins were diluted by increased overseas operations [20][20] Future Outlook - **Earnings Visibility**: The company is expected to benefit from accelerating new order intake in 4Q25 and improving earnings visibility for 2026-28, which is anticipated to drive share price momentum [1][1] - **Market Risks**: Potential risks include geopolitical tensions, continuing order impairments, and slower-than-expected global expansion [21][21] Key Financial Ratios and Estimates - **P/E Ratio**: Expected to decrease from 62.3 in 2024 to 21.7 by 2027 [11][11] - **EPS Growth**: Projected to increase significantly in 2025 by 239.6% [11][11] - **Dividend Yield**: Expected to rise from 1.0% in 2025 to 1.4% by 2027 [11][11] Conclusion Tigermed is positioned to capitalize on the recovery in the clinical CRO sector, with strong financial performance in 3Q25 and a positive outlook for new orders and earnings growth. The company remains a buy recommendation based on its growth potential and market positioning.

2025年10月29日，泰格医药(300347.SZ)发布2025年第三季报。截至2025年10月28日，共有67个机构投 资者披露持有泰格医药A股股份，合计持股量达1.54亿股，占泰格医药总股本的17.91%。其中，前十大 机构投资者包括香港中央结算有限公司、中国工商银行股份有限公司-中欧医疗健康混合型证券投资基 金、中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金、全国社保基金六零一组 合、中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基金、中国工商银行股份有 限公司-华泰柏瑞沪深300交易型开放式指数证券投资基金、招商国证生物医药指数A、诺安先锋混合 A、天弘国证生物医药ETF、天弘医药创新A，前十大机构投资者合计持股比例达16.02%。相较于上一 季度，前十大机构持股比例合计上涨了0.35个百分点。 外资态度来看，本期较上一期持股增加的外资基金共计1个，即香港中央结算有限公司，持股增加占比 达2.91%。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 公募基金方面，本期较上一期持股增加的公募基金共计22个，主要包括诺安先锋混合A、中欧医疗健康 混 ...

Summary of the Conference Call for Tigermed (2025 Q3) Industry Overview - The Chinese biopharmaceutical R&D capability has reached a global leading position, aligning closely with developed markets in Europe and the U.S. [2][3] - Innovative drug assets are becoming core pricing assets globally, although current prices in China remain lower than in developed markets, with expectations for this gap to narrow in the future [2][5] - Emerging market opportunities exist in areas such as weight loss drugs, immuno-oncology 2.0, and small nucleic acids [2][6] - The trend of industry consolidation continues, with leading companies focusing on core areas, as evidenced by a global CICDMO leader selling its clinical CRO and SMO businesses [2][7] Company Performance - In the first three quarters of 2025, Tigermed benefited from active BD and Novo acquisition transactions, with improved capital market liquidity and an optimized exit mechanism for China's innovative drug primary market [2][9] - Tigermed signed new orders totaling nearly 7 billion RMB, with service fees increasing over 20% year-on-year after excluding certain laboratory service orders [2][11] - The proportion of orders from multinational and large domestic pharmaceutical companies has significantly increased, with early clinical trial projects also seeing a rise [2][11] Financial Highlights - Tigermed's revenue for the first three quarters was 5.026 billion RMB, a slight decrease of 0.8% year-on-year, with Q3 revenue at 1.775 billion RMB, up 3.9% [4][13] - Operating cash flow for the first three quarters was 740 million RMB, a 28% increase year-on-year, maintaining strong cash flow for five consecutive quarters [4][12] - The gross profit margin for the first three quarters was 29.2%, down from 38.9% year-on-year, primarily due to impacts from the CTS segment [4][19] Strategic Initiatives - Tigermed is focusing on digitalization and intelligent technology development, launching an AI medical writing platform as part of its strategic initiatives [4][15] - The company plans to continue improving cash flow management and addressing legacy client payment issues [4][12] - Future expectations include a recovery in domestic demand and an increase in overseas clinical trial opportunities, particularly for early evidence generation experiments [4][16] Market Trends and Challenges - The Chinese biopharmaceutical industry is expected to continue integrating into the global R&D system, with significant clinical research opportunities arising from the new cycle [4][24] - Despite challenges from cash flow pressures faced by some clients, the overall market sentiment is positive, with a notable increase in new orders [4][6][24] - The company anticipates a gradual recovery in project pricing and an increase in overseas clinical projects, particularly from multinational clients [4][24] Future Outlook - Tigermed is optimistic about future profit margins, performance, and order growth, driven by the recovery of the innovative drug industry and ongoing digitalization efforts [4][23] - The company plans to expand its workforce cautiously based on order flow and demand, particularly in the clinical operations segment [4][27] - Proactive risk management measures will be implemented to ensure business continuity amid global uncertainties [4][28]

智通财经APP讯，泰格医药(300347.SZ)发布2025年三季度报告，该公司前三季度营业收入为50.26亿 元，同比减少0.82%。归属于上市公司股东的净利润为10.2亿元，同比增长25.45%。归属于上市公司股 东的扣除非经常性损益的净利润为3.26亿元，同比减少63.46%。基本每股收益为1.19元。 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）041 号 一、审议并通过《关于公司2025年第三季度报告的议案》。 公司《2025年第三季度报告》真实、准确、完整地反映了公司2025年第三季度的财务 状况和经营成果，不存在虚假记载、误导性陈述和重大遗漏。 公司审计委员会审议通过本议案，并同意提交董事会审议。 报告详见中国证监会指定的创业板信息披露网站同日披露的相关公告。 表决结果：同意7票，反对0票，弃权0票。 杭州泰格医药科技股份有限公司 第五届董事会第十九次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十九次会议于2025 年10月28日在杭州市滨江区聚工路19号盛大科技园A座19层会议室举行，本次会议以现场 与通讯表决相结合的方式召开。会议通知已于2025年10月14日以电话、电子邮件方式向全 体董事发出。会议应到董事7人，实到董事7人。本次会议由公司董事长叶小平先生主持。 本次会议的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与 ...

格隆汇10月28日丨泰格医药(03347.HK)发布公告，2025年前三季度，实现营业收入50.26亿元(人民币， 下同)，同比减少0.82%；归属于上市公司股东的净利润10.20亿元，同比增加25.45%；归属于上市公司 股东的扣除非经常性损益的净利润3.26亿元，同比减少63.46%；基本每股收益1.19元。 ...